First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).
作者信息
Alfayez Mansour, Thakral Beenu, Jain Preetesh, Ravandi Farhad, Ferrajoli Alessandra, Jain Nitin, Pemmaraju Naveen, Wierda William, Kadia Tapan
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Leuk Lymphoma. 2020 Feb;61(2):445-449. doi: 10.1080/10428194.2019.1660967. Epub 2019 Sep 30.
Abstract
摘要
相似文献
1
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).
Leuk Lymphoma. 2020 Feb;61(2):445-449. doi: 10.1080/10428194.2019.1660967. Epub 2019 Sep 30.
2
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
Acta Oncol. 2020 Dec;59(12):1547-1551. doi: 10.1080/0284186X.2020.1821913. Epub 2020 Sep 24.
3
T-PLL: another check on the venetoclax list?
Blood. 2017 Dec 7;130(23):2447-2448. doi: 10.1182/blood-2017-10-809673.
4
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303.
5
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.
6
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Haematologica. 2021 Aug 1;106(8):2251-2256. doi: 10.3324/haematol.2020.271304.
7
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Blood Adv. 2024 Feb 27;8(4):842-845. doi: 10.1182/bloodadvances.2023012248.
8
Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.
Hematology. 2023 Dec;28(1):2237342. doi: 10.1080/16078454.2023.2237342.
9
B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax.
Leuk Lymphoma. 2020 Mar;61(3):749-752. doi: 10.1080/10428194.2019.1689392. Epub 2019 Nov 12.
10
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
Blood Cancer J. 2021 Mar 2;11(3):47. doi: 10.1038/s41408-021-00443-1.
引用本文的文献
1
Proteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia.
Int J Mol Sci. 2024 Dec 18;25(24):13573. doi: 10.3390/ijms252413573.
2
Recent developments in the identification and biosynthesis of antitumor drugs derived from microorganisms.
Eng Microbiol. 2022 Sep 3;2(4):100047. doi: 10.1016/j.engmic.2022.100047. eCollection 2022 Dec.
3
Prolymphocytic Leukaemia: an Update on Biology and Treatment.
Curr Oncol Rep. 2024 Feb;26(2):129-135. doi: 10.1007/s11912-023-01485-3. Epub 2024 Jan 2.
4
[Simultaneous determination of pentostatin and 2'-amino-2'-deoxyadenosine in fermentation broth by high performance liquid chromatography-tandem mass spectrometry].
Se Pu. 2021 Jul 8;39(7):744-749. doi: 10.3724/SP.J.1123.2020.09018.
5
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias.
Hemasphere. 2021 Jun 1;5(6):e573. doi: 10.1097/HS9.0000000000000573. eCollection 2021 Jun.
6
T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches.
Cureus. 2021 Feb 9;13(2):e13237. doi: 10.7759/cureus.13237.
7
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
Blood Cancer J. 2021 Mar 2;11(3):47. doi: 10.1038/s41408-021-00443-1.
8
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Haematologica. 2021 Aug 1;106(8):2251-2256. doi: 10.3324/haematol.2020.271304.
9
Advances and Perspectives in the Treatment of T-PLL.
Curr Hematol Malig Rep. 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5.
本文引用的文献
1
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).
Bone Marrow Transplant. 2019 Sep;54(9):1391-1398. doi: 10.1038/s41409-019-0448-x. Epub 2019 Jan 21.
2
Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis.
Oncol Lett. 2018 Jul;16(1):301-307. doi: 10.3892/ol.2018.8615. Epub 2018 May 2.
3
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Clin Cancer Res. 2018 Aug 15;24(16):3967-3980. doi: 10.1158/1078-0432.CCR-17-3004. Epub 2018 Apr 17.
4
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.
Cancer Res. 2018 May 1;78(9):2407-2418. doi: 10.1158/0008-5472.CAN-17-3644. Epub 2018 Feb 26.
5
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.
6
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.
7
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.
8
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.
9
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Ann Oncol. 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163.
10
Pathways and mechanisms of venetoclax resistance.
Leuk Lymphoma. 2017 Sep;58(9):1-17. doi: 10.1080/10428194.2017.1283032. Epub 2017 Jan 31.
Zotero 插件